Addition Therapeutics unveiled its PRINT platform and disclosed major financing to develop an all‑RNA, lipid nanoparticle‑based gene insertion technology derived from retrotransposon biology. The company announced both a $106.5 million fundraise and earlier $100 million‑level backing tied to its emergence from stealth, citing support from philanthropic and institutional investors. Addition’s approach uses RNA‑mediated insertion to place therapeutic payloads at a designated genomic safe site, aiming to sidestep challenges tied to viral vectors and permanent random insertion. The startup positions the platform for chronic and rare disease gene therapies and emphasizes LNP delivery as a path to scalable administration. Investors are betting on the potential to combine precision insertion with LNP delivery, but the field will watch insertion fidelity, immunogenicity, and durability as addition seeks translational milestones.